• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Immunogene therapy for the gostrointestinal malignancies using tumor cells engineered to secrete cytokines and chemokines

Research Project

Project/Area Number 09470268
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypeSingle-year Grants
Section一般
Research Field Digestive surgery
Research InstitutionYamaguchi University

Principal Investigator

HAZAMA Shoich  Yamaguchi Univ.Sch.of Med, assistant, 医学部, 助手 (50253159)

Co-Investigator(Kenkyū-buntansha) OKA Masaaki  Yamaguchi Univ.Sch.of Med, professor, 医学部, 教授 (70144946)
Project Period (FY) 1997 – 1998
Project Status Completed (Fiscal Year 1998)
Budget Amount *help
¥4,000,000 (Direct Cost: ¥4,000,000)
Fiscal Year 1998: ¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 1997: ¥2,700,000 (Direct Cost: ¥2,700,000)
KeywordsIL-15 / IL-18 / GM-CSF / MIP-1alpha / gene therapy / cytokine / chemokine / immunotherapy / inter lerkin-18 / mouse / Vaccination
Research Abstract

We examined the effect of IL-15, IL-18, GM-CSF, and MIP-1alpha gene transfer into tumor cells on the host's anti-tumor response. In BALB/c mice IL-15 producing Meth-A cells (Meth-A/IL-15) underwent complete rejection, in a response characterized by massive infiltration of CD4+ T cells and neutrophils. In contrast, Meth-A cells transfected with vector alone (Meth-A/Neo) grew rapidly. Moreover, rechallenged parental cells also were rejected in association with CD8+ T cell infiltration. However, in nude mice there was no drastic difference between Meth-A/IL-15 and Meth-A/Neo cells.
In BALB/c mice IL-18 producing colon 26 cells (mature JL-18/colon 26) underwent complete rejection, in a response characterized by massive infiltration of CD8 + T cells and macro phage. In contrast, colon26 cells transfected with control vector (colon26/control) grew rapidly. Moreover, rechallenged parental cells also were rejected. On the other hand, Rechallenged another cancer cell (Meth A ; Methylcorantrain induced sarcoma) were not rejected.
Next, we examine the effect of multiple cytokine producing tumor cells . Tumors which secrete four kinds of cytokines (IL-15, IL-18, GM-CS F, and MIP-1alpha) were injected subcutaneously of syngeneic mice. These results demonstrate that co-injection of IL-15, IL-18 and GM-CS F secreting tumor cells can stimulate strongest local and systemic T cell-dependent immune reaction.

Report

(3 results)
  • 1998 Annual Research Report   Final Research Report Summary
  • 1997 Annual Research Report
  • Research Products

    (15 results)

All Other

All Publications (15 results)

  • [Publications] Shoichi Hazama, et. al.,: "Tumor Cells Engineered to Secrete Interleukin-15 Augment Anti-tumor Immune Responses in vivo," Brit.J.Cancer,. (in press).

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Shoichi Hazama, et. al.,: "Immunogene Therapy for Cancer : the Current Situation and a Way Forward." Biotherapy. 12(3). 382-386 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] 硲 彰一、他.: "新しいサイトカインを用いた癌免疫遺伝子療法の検討" Biotherapy,. 13(1). 31 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] 硲 彰一、他.: "IL-15による新しい免疫療法の基礎的検討" Biotherapy,. 12(5). 586 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] 吉村 清、他.: "IL-18遺伝子導入腫瘍細胞を用いた癌免疫遺伝子療法の検討." Biotherapy,. 12(5). 727 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Shoichi Hazama, et.al.: "Tumor Cells Engineered to Secrete Interleukin-15 Augment Anti-tumor Immune Responses in vivo" Brit.J.Cancer. (in press).

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Shoichi Hazama, et.al.: "Immunogene Therapy for Cancer : the Current Situation and a Way Forward." Biotherapy. 12 (3). 382-386 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Shoichi Hazama, et.al.: "Immunogene Therapy for Cancer Using Tumor Cells Engineered to Secrete Novel Cytokines" Biotherapy. 13 (1). 31 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Shoichi Hazama, et.al.: "New Immunotherapy Using Novel cytokine ; IL-15" Biotherapy. 12 (5). 586 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Kiyoshi Yoshimura, et.al.: "Cancer Immunogene Therapy Using Tumor Cells Engineered to Secrete Interleukin-18" Biotherapy. 12 (5). 727 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Shoichi Hazama,et al.,: "Tumor Cells Engineered to Secrete Interleukin-15 Augment Anti-tumor Immune Responses in rivo," Brit.J.Cancer,. (in press).

    • Related Report
      1998 Annual Research Report
  • [Publications] 硲 彰一、他.: "新しいサイトカインを用いた癌免疫遺伝子療法の検討" Biotherapy,. 13(1). 31 (1999)

    • Related Report
      1998 Annual Research Report
  • [Publications] 吉村 清、他.: "IL-18遺伝子導入腫瘍細胞を用いた癌免疫遺伝子療法の検討." Biotherapy,. 12(5). 727 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] 硲 彰一, 吉村 清 他: "IL-18遺伝子導入腫瘍細胞を用いた癌免疫遺伝子療法の検討" Biotherapy. 12(5)(in press). (1998)

    • Related Report
      1997 Annual Research Report
  • [Publications] 硲 彰一, 他: "新しいサイトカイン(IL-15,IL-18)を用いた癌免疫遺伝子療法の検討" 日本外科学会雑誌. 99(2)(in press). (1998)

    • Related Report
      1997 Annual Research Report

URL: 

Published: 1997-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi